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ABSTRACT  57 
Background: Quinolones are the second most frequent cause of hypersensitivity 58 
reactions (HSRs) to antibiotics after betalactams. A marked increase in the number of 59 
patients with HSRs to quinolones has been detected.  60 
Objective: To describe the clinical characteristics of patients with HSRs to quinolones 61 
and present methods for their diagnosis. 62 
Methods: Patients attending the allergy unit due to reactions suggestive of HSRs to 63 
quinolones were prospectively evaluated between 2005-2018. Diagnosis was achieved 64 
using clinical history, skin tests (STs), the basophil activation tests (BATs), and drug 65 
provocation tests (DPTs) if ST and BAT were negativeas necessary. 66 
Results: We included 128 subjects confirmed as having HSRs to quinolones and 42 67 
found to be tolerant. Anaphylaxis was the most frequent entity in immediate HSRs and 68 
was most commonly induced by moxifloxacin. Patients were evaluated a median of 150 69 
days (interquartile range: 60-365) after the reaction. Of patients who underwent ST and 70 
BAT, 40.74% and 70% respectively were positive. DPT with a quinolone was 71 
performed in 48 cases, giving different results depending on the culprit drug: when 72 
moxifloxacin was involvedthe culprit, 62.5% of patients gave a positive DPT to 73 
ciprofloxacin, whilst none reacted to levofloxacin. The risk of HSR was 96 times higher 74 
in subjects who reported moxifloxacin-induced anaphylaxis and 18 times higher in 75 
those reporting immediate reactions compared to clinical entities induced by quinolones 76 
other than moxifloxacin and non-immediate reactions. 77 
Conclusions: The diagnosis of HSR to quinolones is complex. The use of clinical 78 
history is essential as a first step. BAT shows higher sensitivity than STs. DPTs can be 79 
useful for finding safe alternative quinolones. 80 
81 
What is already known about this topic? 82 
Quinolones can induce hypersensitivity through several mechanisms, being the third 83 
most common drug associated with hypersensitivity, and the second most frequent drug 84 
inducing both IgE-mediated hypersensitivity and severe anaphylaxis. The optimal 85 
diagnostic approach remains a controversial topic. 86 
What does this article add to our knowledge? 87 
The risk of having quinolone hypersensitivity is higher for immediate reactions, 88 
particularly for moxifloxacin-induced anaphylaxis. The basophil activation test has a 89 
higher sensitivity than skin test. Drug provocation testing can be useful to identify safe 90 
alternative quinolones. 91 
How does this study impact current management guidelines 92 
We propose an algorithm for diagnosing quinolone-induced reactions, which should be 93 
classified according to the interval between drug intake and reaction onset, using a 6 94 
hour threshold. The algorithm includes skin, basophil activation, and drug provocation 95 
tests as necessary. 96 
97 
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INTRODUCTION  109 
Quinolones are antibiotics that are commonly prescribed for their effectiveness against 110 
Gram (+) and Gram (-) bacteria1-3. Adverse effects occur in 2-10% of people taking 111 
quinolones, however most of them are mild, mainly affecting the gastrointestinal or 112 
central nervous systems3,4. Quinolones can induce hypersensitivity reactions (HSRs)5 113 
through IgE-mediated reactions (immediate reactions, IRs) and T-cell dependent 114 
reactions (non-immediate reactions, NIRs)6,7. In addition, quinolones may also cause 115 
HSRs in drug-naïve patients8,9. A mechanism of mast cell activation via occupation of 116 
the human Mast-related G-protein receptor X2 (MRGPRX2) has been described for 117 
IRs10,11 occurring in patients without previous exposure to quinolones12.   118 
Although the absolute risk of an HSR related to quinolones is low (44.0 (95% CI: 34.8–119 
53.3) emergency department visits/100,000 prescriptions)8, quinolones are the third 120 
most frequent drug associated with HSRs13 in general, and the second most frequent in 121 
IgE-mediated HSRs. They are also the second most frequent cause of alert activation for 122 
antibiotic allergy in electronic hospital records14 and severe drug-induced 123 
anaphylaxis13,15. In recent years, an increase in the percentage of patients with HSRs to 124 
these drugs has been detected, ranging from 0.54% in 2005 to 6.85% in 201013. This is 125 
likely due to their increased prescription over the last decades16. The incidence of 126 
anaphylaxis induced by quinolones has been estimated to be 1.8–23 per 10 million days 127 
of treatment17,18 and the prevalence of cutaneous adverse reaction to be 0.09%19. 128 
Quinolones are also one of the main triggers of acute generalized exanthematous 129 
pustulosis (AGEP), photosensitivity and vasculitis20. 130 
HSRs to quinolones appear in an important percentage of patients (23%) previously 131 
diagnosed as allergic to betalactams: in fact, betalactam allergic patients have a 17 times 132 
higher risk of reacting to quinolones than those non-allergic. This represents an 133 
important health problem as it greatly decreases therapeutic options availables16. In a 134 
large study of inpatients with common infections requiring antibiotic treatment, 135 
quinolone allergy occurred in 5.4% of patients who were already sensitive to 136 
betalactams21, leading to important restrictions for antibiotic prescription and 137 
subsequently poor prognosis of their infections. 138 
The optimal diagnosis of quinolone HSRs is still a matter of debate. The value of skin 139 
tests (STs) is uncertain, and they have shown false positive results when quinolones are 140 
tested at high concentration22-25. The presence of specific IgE to quinolones has been 141 
reported using the sepharose radioimmunoassay, with a sensitivity of 54.5%26. The 142 
basophil activation test (BAT) has shown promising results for the diagnosis of patients 143 
with IRs to quinolones27-29. However, other studies have contradicted these findings30,31. 144 
The gold standard, therefore, is the drug provocation test (DPT). However, this is not 145 
free of risk and not advisable in cases where the reaction might be severe. 146 
The aim of this study was to describe the clinical characteristics of a large group of 147 




We prospectively evaluated patients with symptoms suggestive of HSR to quinolones 152 
that had been referred to the Allergy unit of the University Regional Hospital of 153 
Málaga, University Hospital of Salamanca, and of the University Hospital La Fe of 154 
Valencia over a period of 13 years (2005-2018).  155 
Inclusion criteria. Patients ≥14 years-old in whom the allergological study was 156 
completed were included and classified in two groups: A) Patients confirmed as having 157 
HSRs to quinolones (by positive STs, BATs or DPTs); and B) Patients confirmed as 158 
being non-allergic (tolerant) as they tolerated a DPT with the suspected culprit 159 
quinolone.  160 
Exclusion criteria. Patients <14 years-old; patients in whom the allergological study 161 
was not completed so that the diagnosis could not be confirmed as being neither allergic 162 
nor tolerant to quinolones: pregnant or breastfeeding patients; patients taking beta-163 
blockers or ACE inhibitors or with contraindications for epinephrine administration; 164 
patients who had acute infections and/or underlying cardiac, hepatic or renal diseases 165 
that contraindicated DPTs; and subjects with psychosomatic disorders. 166 
Clinical history 167 
Patients were asked about their reaction symptoms32, the interval between drug intake 168 
and reaction onset, the number of episodes, the interval between their last reaction and 169 
the study, and the presence of other underlying diseases. If a reported reaction occurred 170 
within 6 hours after quinolone intake, the reaction was classified as IR; when this 171 
interval was longer, it was considered an NIR5,32. 172 
Skin testing 173 
For reactions suggestive of an IR, skin prick tests (SPTs) were carried out as described33 174 
using ciprofloxacin (at 0.02 and 0.2 mg/ml), levofloxacin (at 0.05 and 0.5 mg/ml), and 175 
moxifloxacin (one tablet of 400 mg suspended in NaCI). Intradermal tests were not 176 
performed to avoid false positive results as non-specific histamine release by quinolones 177 
has been reported34,35. 178 
For reactions suggestive of an NIR, patch tests (PTs) were carried out and evaluated as 179 
described33 by mixing powdered quinolone (ciprofloxacin, levofloxacin, and 180 
moxifloxacin) in petrolatum at 30% w/w.  181 
Basophil activation test 182 
In patients with a suspected IR, BATs were performed as described previously27, using 183 
ciprofloxacin (2 and 0.2 mg/ml), levofloxacin (4 and 2 mg/ml), moxifloxacin (2, 0.2 and 184 
0.1 mg/ml), norfloxacin (2, 0.2 and 0.1 mg/ml), ofloxacin (4, 2, 0.2 and 0.1 mg/ml), and 185 
lomefloxacin (4, 2, 0.2 and 0.1 mg/ml).  186 
Drug provocation test 187 
DPTs with ciprofloxacin, levofloxacin, and moxifloxacin were performed in a single 188 
blind manner if skin tests and BATs were negative36: placebo capsules were given at 189 
different times on the first day; increasing doses of quinolones were administered orally 190 
at intervals of 60 min (5, 20, 100 mg for ciprofloxacin and levofloxacin; 5, 30, 65 mg 191 
for moxifloxacin) on the second day. If these did not produce a reaction, three further 192 
doses of quinolones were given on the third day: 125, 125, 250 mg (accumulative dose 193 
500 mg) for ciprofloxacin and levofloxacin; 100, 100, 200 mg (accumulative dose 400 194 
mg) for moxifloxacin. The three test days were separated by 1 week. If cutaneous and/or 195 
respiratory symptoms or alterations in vital signs appeared, the procedure was stopped 196 
and the symptoms were evaluated and treated. If no symptoms appeared during graded 197 
challengedrug administration, the therapeutic dose of quinolone was achieved. T and 198 
this was then followed by taking the full 2 days at maximum dose at home, starting after 199 
a gap of 24 hours after the graded challenge. Before beginning the DPT procedure, 200 
patients were stable and their forced expiratory volume in 1s had to be at least 80% of 201 
the predicted value, with an absolute volume of at least 1.5 L. Medications were stopped 202 
before DPT according to international guidelines36.  203 
Statistical analysis 204 
Data analysis was performed using Chi-square analysis to test differences in nominal 205 
variables between groups, the Fisher test was used when there were no criteria for using 206 
the Chi-square test and the Mann–Whitney test was used for quantitative variables. All 207 
reported p values represented two-tailed tests, with values <0.05 considered statistically 208 
significant. A logistic regression analysis was performed to establish the characteristics 209 
associated with the diagnosis of HSR or tolerance to quinolones and with the diagnosis 210 
of immediate anaphylaxis. The following variables were analysed: gender, age, time 211 
interval between drug intake and the onset of the reaction, symptoms experienced, drugs 212 
involved, time interval between drug reaction and study, and number of episodes. 213 
The study was conducted according to the principles of the Declaration of Helsinki. All 214 
the participants were informed orally about the study and signed the corresponding 215 
informed consent. 216 
217 
RESULTS  218 
A total of 612 patients with a clinical history suggestive of an HSR to quinolones were 219 
evaluated. Of these, full diagnosis could not be achieved for 442 patients: 361 patients 220 
that gave a negative ST and negative BAT could not undergo DPT to quinolones due to 221 
age, comorbidities or because it was contraindicated due to the potential severity of the 222 
reaction; 78 did not give consent for the allergological tests (STs, BAT and/or DPTs); 223 
and 3 were excluded due to pregnancy. For the remaining 170 patients a full diagnosis 224 
could be achieved: 128 were confirmed as having HSRs to quinolones and 42 as non-225 
allergic (tolerant) to quinolones.  226 
Clinical data of the subjects included in the study 227 
The 170 included subjects with confirmed diagnosis had a median age of 53 228 
[interquartile range: 40–63.25] years, and 126 (74.1%) were female. The majority of 229 
cases reported only one previous episode induced by quinolone intake, except for 2 230 
cases who reported 2 previous IRs. As such, the patients included in the study reported a 231 
total of 172 previous reactions: 120 IRs and 52 NIRs, with the percentage of IRs higher 232 
in those confirmed as having HSRs compared to the tolerant group (73.8% vs 19%; 233 
p<0.0001) (Table 1). Most reported reactions were induced by oral quinolones (142; 234 
82.5%), the rest by intravenous route (30;17.4%). In terms of the symptoms of reported 235 
reactions, the percentage of anaphylaxis reactions was higher in subjects confirmed as 236 
having HSR (p<0.0001); whereas urticaria (p=0.0004), local reaction at the site of IV 237 
administration (p=0.0001) and MPE (p=0.03) were more frequently report by subjects 238 
that were found to be as tolerant (Table 1). Moxifloxacin was the most frequent culprit 239 
quinolone in patients with confirmed HSRs; ciprofloxacin was more frequent in subjects 240 
confirmed as tolerant (p<0.0001 and p=0.001, respectively) (Table 1). In subjects 241 
confirmed as having HSRs, most cases of anaphylaxis were induced by moxifloxacin 242 
(52.9%; p=0.002); urticaria and angioedema were mostly induced by ciprofloxacin 243 
(48.8% and 66.7%, respectively), although these differences was not found to be 244 
statistically significant (Table E1). For those found to be tolerant, ciprofloxacin was the 245 
most frequent cause of both urticaria and angioedema (69.2% and 66.7%, respectively), 246 
as well as of local reactions at the site of IV administration (66.7%) (p>0.05) (Table 247 
E1).  248 
The logistic regression analysis showed that the risk of being confirmed as HSR was 249 
higher for cases who reported moxifloxacin-induced anaphylaxis (OR: 96.16; CI: 6.172-250 
Inf; p=0.009) and for those reporting IRs (OR: 18.856; CI: 5.196-271.449; p<0.0001) 251 
compared to cases who reported other symptoms induced by other quinolones and 252 
NIRs. Moreover, the risk for being confirmed as HSR decreased when ciprofloxacin 253 
was the culprit (OR: 0.107; CI: 0.002-0.741; p=0.04) and the symptoms reported were 254 
MPE, FDE, urticaria, angioedema (OR: 0.053; CI: 0-0.452; p=0.03), or a local reaction 255 
at the site of IV administration (OR: 0.001; CI: 0-0.016; p=0.0006). No significant 256 
associations were found for the other variables, and there were no interactions between 257 
variables. 258 
Analysis of the patients confirmed as suffering HSRs to quinolones 259 
In patients confirmed as having HSRs, a total of 112 reported reactions (73.8%) were 260 
IRs and 18 (26.2%) NIRs. No differences were found when comparing age, sex, atopy, 261 
allergen sensitization and underlying diseases between IR and NIR groups (data not 262 
shown).   263 
Anaphylaxis was the most frequent reported symptom among IRs (p<0.0001) and 264 
urticaria among NIRs (p>0.05) (Table 2). It is of note that the 7 (25%) of patients 265 
reporting reactions within the interval of 1-6 hours showed symptoms compatible with 266 
anaphylaxis. Moxifloxacin was the most frequent quinolone involved in IRs and 267 
ciprofloxacin in NIRs (41.1% and 38.9%, respectively) (Table 2). Anaphylaxis was 268 
induced primarily by moxifloxacin in IRs (52.9%; OR=2.935 (IC:1.418-6.075), 269 
p=0.003)  whereas most urticaria and angioedema was induced by ciprofloxacin (52.9% 270 
and 75%, respectively). Considering NIRs, moxifloxacin was the culprit in most cases 271 
reporting urticaria (42.8%) and ciprofloxacino in angioedema reporting-cases (50%) 272 
(Table E2). The time interval between intake and onset of the reaction was shorter when 273 
the drug was administered by an IV route compared to the oral route (5 [IR: 5-10] 274 
minutes vs 30 [IR: 15-60] minutes, p=0.005). This comparison was also statistically 275 
significant when ciprofloxacin was the culprit (IV route: 5 [5-10] minutes; oral route: 30 276 
[18.7-165] minutes; p=0.01) (Table E3).  277 
Methods used for diagnosis 278 
The median time interval between the reaction and the study was 150 days [interquartile 279 
range: 60-365] (mean: 560.3 days, SD: 1028.4 days). No differences were found 280 
between IRs and NIRs. STs were performed on 54 subjects, BATs on 76, and DPTs on 281 
48. No differences were found when comparing the clinical characteristics of patients 282 
undergoing the different tests (data not shown).  283 
Skin tests 284 
SPTs were performed on 48 patients and PTs on 6, of which 22 were positive: 20 SPTs  285 
and 2 PTs. Of the positive SPTs, 13 (43.33%) were positive to moxifloxacin, 7 (8.53%) 286 
to ciprofloxacin, and 6 (9.83%) to levofloxacin (Table 3). When ciprofloxacin was the 287 
suspected culprit drug, SPTs to ciprofloxacin were positive in 16.7% of the tests and 288 
levofloxacin in 22.2%; when levofloxacin was the suspected culprit, 25% of SPTs were 289 
positive to levofloxacin and 80% to moxifloxacin. Finally, when the suspected culprit 290 
was moxifloxacin, 100% of SPTs were positive to moxifloxacin and 6.2% to 291 
ciprofloxacin (Table 3). Regarding the symptomatology of the reported reactions, the 292 
highest percentage of positive ST results was found for anaphylaxis (53.8%), followed 293 
by urticaria (33.3%). Although the interval between the last quinolone-induced reaction 294 
and the study was shorter in patients with positive STs compared to negative, no 295 
statistical difference was found (90 [interquartile range: 60-240] vs 120 [interquartile 296 
range: 60-172.5] days; p=1). 297 
Basophil activation test 298 
The BAT was positive in 68 (89.5%) of cases. A total of 56 (76.7%) cases were positive 299 
to ciprofloxacin, 35 (53.8%) to moxifloxacin, 26 (44.1%) to levofloxacin, 15 (83.3%) to 300 
norfloxacin, 10 (58.8%) to ofloxacin and 10 (55.5%) to lomefloxacin (Table 46). When 301 
ciprofloxacin was the culprit, BAT to ciprofloxacin was positive in 80%, to 302 
moxifloxacin in 60% and to levofloxacin in 47.4%; when levofloxacin was the culprit, 303 
BAT was positive to ciprofloxacin in 72.7%, to levofloxacin in 45.4% and to 304 
moxifloxacin in 20%; finally, when the culprit drug was moxifloxacin, BAT was 305 
positive to ciprofloxacin in 76.5%, to moxifloxacin in 62.5% and to levofloxacin in 306 
46.2% (Table 46). BAT was positive in 48 out of 49 (97.9%) cases reporting 307 
anaphylaxis, in 13 out of 18 (72.2%) cases of urticaria and in 5 (100%) cases of 308 
angioedema. Although the interval between the historical quinolone reaction and 309 
whether the patients were found to be allergic or not in the study was shorter in patients 310 
who gave a positive BAT compared to negative,  no statistical differences were found 311 
(150 [interquartile range: 60-365] vs 395 [interquartile range: 60-1003.7] days; 312 
p=0.9909). 313 
Drug provocation test 314 
We performed 58 DPTs in 48 patients. A total of 34 DPTs with the culprit quinolone 315 
were carried out in cases with negative ST and BAT, all of which were positive: 23 in 316 
IR (16 with ciprofloxacin, 3 with levofloxacin, and 4 with moxifloxacin) and 11 in NIR 317 
(5 with ciprofloxacin, 2 with levofloxacin, and 4 with moxifloxacin). When the benefit 318 
was considered to outweigh the risk, we carried out DPTs with an alternative quinolone 319 
in 24 cases, this was positive for 13 of these (11 IR and 2 NIR) (Table 5). When 320 
ciprofloxacin was the culprit, DPT to levofloxacin was positive in 60%; when 321 
levofloxacin was the culprit, DPT was positive to ciprofloxacin in 40%; when the 322 
culprit drug was moxifloxacin, DPT was positive to ciprofloxacin in 62.5%, and no case 323 
reacted to levofloxacin (Table 5). In all cases DPTs with quinolones induced mild 324 
symptoms (pruritus and wheals localized on different parts of the body) that 325 
disappeared 1-48 hours after administering antihistamine and corticosteroid treatment.  326 
DISCUSSION 327 
Although hypersensitivity reactions (HSRs) to quinolones represent an important health 328 
problem 21, no large-scale study of patients suffering from them exists. To our 329 
knowledge, this is the largest published series of HSRs to quinolones to date. In our 330 
study, more than the 50% of patients reported anaphylaxis, most of whom suffered from 331 
immediate reactions (IRs), in agreement with previously published short 332 
series24,26,27,30,34. Moreover, data suggests that the risk of an HSR is different depending 333 
on the quinolone. Analyses of spontaneous reports implicate moxifloxacin triggers 334 
anaphylaxis in a higher proportion of cases than levofloxacin or ciprofloxacin8,9,37, 335 
which is in line with our results. Indeed, the risk of experiencing anaphylaxis was 2.2-336 
fold higher when moxifloxacin was the culprit, which agrees with previously published 337 
data8,9,37. This may be due to the expanded use of quinolones or increased 338 
immunogenicity to newer quinolones. 339 
The interval between drug intake and the appearance of symptoms is crucial for 340 
evaluating allergic reactions to drugs. Historically, reactions occurring less than one 341 
hour after drug intake are considered IRs, and those occurring after an hour are 342 
considered NIRs5,38. The former are thought to be induced by an IgE-mediated response, 343 
although an alternative non-IgE dependent mechanism may also be involved 10,11. For 344 
the latter, the underlying mechanism remains a matter of debate, especially for those 345 
with a time interval of 1 to 6 hours after drug intake39-41. For betalactam antibiotics, the 346 
mechanism has been proposed to be non-IgE dependent, as some evidence suggests that 347 
these reactions are T-cell mediated40-41. On the other hand, for metamizole, a study of 348 
reactions occurring 1–8 hours after intake using basophil activation testing support an 349 
IgE-mediated42. However, to our knowledge, this mechanism has not yet been studied 350 
for quinolones. In this study, we have observed that around 25% of patients reported 351 
anaphylaxis 1 hour after quinolone intake, and more than 40% of them showed positive 352 
results via BAT or SPT, suggesting that an IgE mechanism is likely. The interval 353 
between drug administration and reaction onset may be related to the production of as-354 
yet unidentified metabolites and the route of administration. However, most patients in 355 
our study took the quinolone orally and no differences could be found in terms of 356 
administration route when considering drugs involved and symptoms reported. As such, 357 
we would suggest that the classification of reactions as IR or NIR based solely on a 1 358 
hour cut-off does not sufficiently reflect the extension of the pathophysiology of the 359 
reactions.  360 
The diagnosis of HSRs to quinolones is still a matter of debate. A detailed clinical 361 
history is crucial as a first approach. We found that the chance of being confirmed as 362 
having an HSR to quinolones was 96 times higher in patients who reported 363 
moxifloxacin-induced anaphylaxis and 18 times higher in those reporting IRs. This risk 364 
decreased when ciprofloxacin was the culprit and the symptoms experienced in the 365 
reported reaction were MPE, FDE, urticaria, angioedema or a local reaction at the site 366 
of the administration of the drug. Concerning STs, there is controversy regarding their 367 
utility. Some authors consider they are useful, with a sensitivity of 71%, specificity of 368 
86%, and positive and negative predictive values of 50% and 94%, respectively having 369 
been reported previously24. However, other studies suggest that STs are not valid 370 
because they can produce false-negatives34,35, potentially missing important reactions 371 
and putting patients at risk, moreover they can also produce a large number of false-372 
positive results when tested at high concentrations, which is attributed to non-specific 373 
histamine release by quinolones due to mast cell activation35,43-48. We decided not to 374 
perform intradermal tests in our patients based on this consideration. In our study, we 375 
found a low sensitivity for STs in general, although it was higher for severe reactions 376 
(anaphylaxis) and when levofloxacin and ciprofloxacin were the culprits.  377 
We found the BAT to be useful for the diagnosis of patients with IRs to quinolones27-29. 378 
However, other studies have shown contradictory results30,31. Here, BAT gave a higher 379 
percentage of positive results than STs, agreeing with previous studies27,28. This is 380 
important, because if BATs can be used to confirm diagnosis instead of DPTs in some 381 
cases, this will reduce patient risk. This is particularly useful here, given that the most 382 
common clinical entity induced by quinolones is anaphylaxis. 383 
Although cross-reactivity among quinolones remains a controversial issue, DPTs could 384 
be useful to find safe alternative quinolones. A high degree of cross-reactivity has been 385 
reported between the first- and second- generation quinolones22. Regarding the second 386 
generation, cross-reactivity does not always occur within this group43,45,49,  which may 387 
be due to the production of different metabolites. The same phenomenon can occur for 388 
the newer (moxifloxacin) and the second- (ciprofloxacin) and third-generation 389 
(levofloxacin) quinolones50-52. A low degree of cross-reactivity has been found between 390 
levofloxacin and ciprofloxacin34. In our study, 60% of the patients who reported 391 
reactions induced by levofloxacin tolerated ciprofloxacin in DPT and 40% of cases  392 
tolerated levofloxacin when the reactions were induced by ciprofloxacin. DPT with 393 
levofloxacin was carried out for 2 cases who reported moxifloxacin-induced reactions,  394 
with neither patient experiencing an adverse reaction. Based on the data obtained from 395 
our large series of cases, we propose an algorithm for the diagnosis of quinolone-396 
induced HSRs, as described in Figure 1. 397 
A limitation of this study is the high percentage of patients for whom we were not able 398 
to confirm the diagnosis due contraindication or patient refusal. This could be the 399 
reason why the number of cases confirmed as tolerant in our series is low. However, 400 
despite this, our results show relevant differences in clinical characteristics comparing 401 
tolerant and cases confirmed as HSRs, highlighting the importance of a detailed clinical 402 
history as an initial approach for diagnosis. Another limitation of our study is that ST, 403 
BAT, and DPT could not be performed for all patients and with all quinolones, that PT 404 
was carried out at a 30% dilution in petrolatum which could increase the rate of false 405 
negative results, and that the time interval between the reaction and the allergy 406 
evaluation was not uniform in all patients. However, our aim was to describe the role 407 
and utility of the different diagnostic methods performed in a large group of patients in 408 
real allergological practice, not finding differences in the clinical characteristics when 409 
comparing groups of patients based on results for ST, BAT, and DPT.  410 
The accurate diagnosis of quinolone-induced HSRs is an important issue not only due to 411 
their frequency, as described above, but also due to the fact that an important percentage 412 
of patients that report quinolone-induced HSRs report previous reactions to betalactams, 413 
drastically reducing their therapeutic options16. Referring patients with quinolone-414 
induced HSRs for a full allergological evaluation is crucial to confirm or dismiss their 415 
reported allergy. 416 
  417 
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Table 1. Clinical data for the reactions reported by the subjects included in the study, comparing cases confirmed as having HSRs to quinolones 573 
and those confirmed as tolerant to these drugs. AE: Angioedema. FDE: Fixed drug eruption. HSR: Hypersensitivity reaction. MPE: 574 










symptoms; n (%) 
Anaphylaxis 70 (53.8) - <0.0001 
Urticaria 41 (31.5) 26 (61.9) 0.0004 
AE 12 (9.2) 6 (14.3) 0.3522 
FDE 4 (3.1) - 0.5732 
MPE 3 (2.3) 4 (9.5) 0.03 
    
Local reaction at the site of intravenous 
administration 
- 6 (14.3) 0.0001 
Drugs involved in 
historical reactions; n 
(%) 
Ciprofloxacin 49 (37.7) 28 (66.7) 0.001 
Levofloxacin  21 (16.2) 10 (23.8) 0.2618 
Moxifloxacin  52 (40) 2 (4.8) <0.0001 
Norfloxacin 3 (2.3) 2 (4.8) 0.5967 
Ofloxacin 1 (0.8) - 1 
Pipemidic acid 2 (1.5) - 1 
Unknown 2 (1.5) - 1 
Time interval intake-reaction, 
median (IR) (min) 
30 (11.25-60) 7200 (2880-8640) <0.0001 
Time interval intake-reaction ≤1h; n (%) 112 (73.8) 8 (19) 
<0.0001 
Time interval intake-reaction >1h; n (%) 18 (26.2) 34 (81) 
Administration route; n (%) 
Oral 109 (83.8) 33 (78.6) 
0.4335 
Intravenous 21 (16.1) 9 (21.4) 
Number of episodes, median (IR) 1 (1-1) 1 (1-1) 0.08 
578 
Table 2.  Clinical data for the reported reactions in cases confirmed as HSRs to 






Immediate                      
n (%) 
Non-immediate        
n (%) 
p 





Urticaria 34 (30.4) 7 (38.9) 0.4696 
AE 8 (7.1) 4 (22.2) 0.04 
FDE - 4 (22.2) 0.0002 
MPE - 3 (16.7) 0.002 
     
Drugs involved 
in historical 
reaction; n (%) 
Ciprofloxacin 42 (37.5) 7 (38.9) 0.9101 
Levofloxacin 17 (15.2) 4 (22.2) 0.451 
Moxifloxacin 46 (41.1) 6 (33.3) 0.5339 
Norfloxacin 2 (1.8) 1 (5.6) 0.3629 
Ofloxacin 1 (0.9) - 1 
Pipemidic acid 2 (1.8) - 1 
Unknown 2 (1.8) - 1 
 
Table 3. Results of SPTs according to the drugs involved and the drug tested. 
 
 
  Drugs tested; positive cases/cases in which the test was performed (%) 










Ciprofloxacin 3/18 (16.7%) 2/9 (22.2%) - 5/27 (18.5%) 
Levofloxacin 0/8 2/8 (25%) 4/5 (80%) 6/21 (28.6%) 
Moxifloxacin 1/16 (6.2%) 0/9 7/7 (100%) 8/34 (23.5%) 
Norfloxacin 0/1 0/1 - 0/2 
Pipemidic 
acid 
2/2 (100%) 1/1 (100%) 1/1 (100%) 4/4 (100%) 
Unknown 1/1 (100%) 1/1 (100%) 1/1 (100%) 3/3 (100%) 
Total 7/46 (15.2%) 6/29 (20.7%) 13/14 (92.8%)  
Table 4. Results of BATs according to the drugs involved and the drug tested. 
 
  Drugs tested; positive cases/cases in which the test was performed (%) 










Ciprofloxacin 20/25 (80%) 9/19 (47.4%) 12/20 (60%) 5/6 (83.3%) 2/6 (33.3%) 4/6 (66.7%) 24/26 (92.3%) 
Levofloxacin 8/11 (72.7%) 5/11 (45.45%) 2/10 (20%) 1/1 (100%) - 0/1 10/12 (83.3%) 
Moxifloxacin 26/34 (76.5%) 12/26 (46.2%) 20/32 (62.5%) 9/10 (90%) 8/10 (80%) 6/10 (60%) 32/35 (91.4%) 
Norfloxacin 1/1 (100%) 0/1 0/1 - - - 1/1 (100%) 
Ofloxacin 1/1 (100%) 0/1 1/1 - - - 1/1 (100%) 
Unknown 0/1 0/1 0/1 0/1 0/1 0/1 0/1 
Total 56/73 (76.7%) 26/59 (44.1%) 35/65 (53.8%) 15/18 (83.3%) 10/17 (58.8%) 10/18 (55.5%)  






Drugs used in DPT; positive cases/cases in which 
the test was performed (%) 






which the test 
was performed 
(%) 
Ciprofloxacin 21/21 3/5 (60%) - 
Levofloxacin 2/5 (40%) 5/5 0/1 
Moxifloxacin 5/8 (62.5%) 0/2 8/8 
Norfloxacin 1/1 (100%) 1/1 (100%) - 





Figure 1. Algorithm proposed for the diagnosis of quinolone induced-HSRs. AGEP: 
Acute generalized exanthematous pustulosis. DPT: Drug provocation test. PT: Patch 
test. SJS: Stevens-Johnson syndrome. SPT: Skin prick test. TEN: Toxic epidermal 
necrolysis. 
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ABSTRACT  57 
Background: Quinolones are the second most frequent cause of hypersensitivity 58 
reactions (HSRs) to antibiotics. A marked increase in the number of patients with HSRs 59 
to quinolones has been detected.  60 
Objective: To describe the clinical characteristics of patients with HSRs to quinolones 61 
and present methods for their diagnosis. 62 
Methods: Patients attending the allergy unit due to reactions suggestive of HSRs to 63 
quinolones were prospectively evaluated between 2005-2018. Diagnosis was achieved 64 
using clinical history, skin tests (STs), basophil activation tests (BATs), and drug 65 
provocation tests (DPTs) if ST and BAT were negative. 66 
Results: We included 128 subjects confirmed as having HSRs to quinolones and 42 67 
found to be tolerant. Anaphylaxis was the most frequent entity in immediate HSRs and 68 
was most commonly induced by moxifloxacin. Patients were evaluated a median of 150 69 
days (interquartile range: 60-365) after the reaction. Of patients who underwent ST and 70 
BAT, 40.7% and 70% respectively were positive. DPT with a quinolone was performed 71 
in 48 cases, giving results depending on the culprit drug: when moxifloxacin was 72 
involved, 62.5% of patients gave a positive DPT to ciprofloxacin, whilst none reacted to 73 
levofloxacin. The risk of HSR was 96 times higher in subjects who reported 74 
moxifloxacin-induced anaphylaxis and 18 times higher in those reporting immediate 75 
reactions compared to clinical entities induced by quinolones other than moxifloxacin 76 
and non-immediate reactions. 77 
Conclusions: The diagnosis of HSR to quinolones is complex. The use of clinical 78 
history is essential as a first step. BAT shows higher sensitivity than STs. DPTs can be 79 
useful for finding safe alternative quinolones. 80 
  81 
What is already known about this topic? 82 
Quinolones can induce hypersensitivity through several mechanisms, being the third 83 
most common drug associated with hypersensitivity, and the second most frequent drug 84 
inducing both IgE-mediated hypersensitivity and severe anaphylaxis. The optimal 85 
diagnostic approach remains a controversial topic. 86 
What does this article add to our knowledge? 87 
The risk of having quinolone hypersensitivity is higher for immediate reactions, 88 
particularly for moxifloxacin-induced anaphylaxis. The basophil activation test has a 89 
higher sensitivity than skin test. Drug provocation testing can be useful to identify safe 90 
alternative quinolones. 91 
How does this study impact current management guidelines 92 
We propose an algorithm for diagnosing quinolone-induced reactions, which should be 93 
classified according to the interval between drug intake and reaction onset, using a 6 94 
hour threshold. The algorithm includes skin, basophil activation, and drug provocation 95 
tests as necessary. 96 
 97 
KEYWORDS: Adverse drug reaction; Anaphylaxis; Basophil activation test; 98 
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Quinolones; Skin tests. 100 
 101 
ABBREVIATIONS: Acute generalized exanthematous pustulosis (AGEP); Basophil 102 
activation test (BAT); Drug provocation test (DPT); Fixed drug eruption (FDE); 103 
Hypersensitivity reaction (HSR); Immediate reaction (IR); Intravenous (IV); 104 




INTRODUCTION  109 
Quinolones are antibiotics that are commonly prescribed for their effectiveness against 110 
Gram (+) and Gram (-) bacteria1-3. Adverse effects occur in 2-10% of people taking 111 
quinolones, however most of them are mild, mainly affecting the gastrointestinal or 112 
central nervous systems3,4. Quinolones can induce hypersensitivity reactions (HSRs)5 113 
through IgE-mediated reactions (immediate reactions, IRs) and T-cell dependent 114 
reactions (non-immediate reactions, NIRs)6,7. In addition, quinolones may also cause 115 
HSRs in drug-naïve patients8,9. A mechanism of mast cell activation via occupation of 116 
the human Mast-related G-protein receptor X2 (MRGPRX2) has been described for 117 
IRs10,11 occurring in patients without previous exposure to quinolones12.   118 
Although the absolute risk of an HSR related to quinolones is low (44.0 (95% CI: 34.8–119 
53.3) emergency department visits/100,000 prescriptions)8, quinolones are the third 120 
most frequent drug associated with HSRs13 in general, and the second most frequent in 121 
IgE-mediated HSRs. They are also the second most frequent cause of alert activation for 122 
antibiotic allergy in electronic hospital records14 and severe drug-induced 123 
anaphylaxis13,15. In recent years, an increase in the percentage of patients with HSRs to 124 
these drugs has been detected, ranging from 0.54% in 2005 to 6.85% in 201013. This is 125 
likely due to their increased prescription over the last decades16. The incidence of 126 
anaphylaxis induced by quinolones has been estimated to be 1.8–23 per 10 million days 127 
of treatment17,18 and the prevalence of cutaneous adverse reaction to be 0.09%19. 128 
Quinolones are also one of the main triggers of acute generalized exanthematous 129 
pustulosis (AGEP), photosensitivity and vasculitis20. 130 
HSRs to quinolones appear in an important percentage of patients (23%) previously 131 
diagnosed as allergic to betalactams: in fact, betalactam allergic patients have a 17 times 132 
higher risk of reacting to quinolones than those non-allergic. This represents an 133 
important health problem as it greatly decreases therapeutic options availables16. In a 134 
large study of inpatients with common infections requiring antibiotic treatment, 135 
quinolone allergy occurred in 5.4% of patients who were already sensitive to 136 
betalactams21, leading to important restrictions for antibiotic prescription and 137 
subsequently poor prognosis of their infections. 138 
The optimal diagnosis of quinolone HSRs is still a matter of debate. The value of skin 139 
tests (STs) is uncertain, and they have shown false positive results when quinolones are 140 
tested at high concentration22-25. The presence of specific IgE to quinolones has been 141 
reported using the sepharose radioimmunoassay, with a sensitivity of 54.5%26. The 142 
basophil activation test (BAT) has shown promising results for the diagnosis of patients 143 
with IRs to quinolones27-29. However, other studies have contradicted these findings30,31. 144 
The gold standard, therefore, is the drug provocation test (DPT). However, this is not 145 
free of risk and not advisable in cases where the reaction might be severe. 146 
The aim of this study was to describe the clinical characteristics of a large group of 147 




We prospectively evaluated patients with symptoms suggestive of HSR to quinolones 152 
that had been referred to the Allergy unit of the University Regional Hospital of 153 
Málaga, University Hospital of Salamanca, and of the University Hospital La Fe of 154 
Valencia over a period of 13 years (2005-2018).  155 
Inclusion criteria. Patients ≥14 years-old in whom the allergological study was 156 
completed were included and classified in two groups: A) Patients confirmed as having 157 
HSRs to quinolones (by positive STs, BATs or DPTs); and B) Patients confirmed as 158 
being non-allergic (tolerant) as they tolerated a DPT with the suspected culprit 159 
quinolone.  160 
Exclusion criteria. Patients <14 years-old; patients in whom the allergological study 161 
was not completed so that the diagnosis could not be confirmed as being neither allergic 162 
nor tolerant to quinolones: pregnant or breastfeeding patients; patients taking beta-163 
blockers or ACE inhibitors or with contraindications for epinephrine administration; 164 
patients who had acute infections and/or underlying cardiac, hepatic or renal diseases 165 
that contraindicated DPTs; and subjects with psychosomatic disorders. 166 
Clinical history 167 
Patients were asked about their reaction symptoms32, the interval between drug intake 168 
and reaction onset, the number of episodes, the interval between their last reaction and 169 
the study, and the presence of other underlying diseases. If a reported reaction occurred 170 
within 6 hours after quinolone intake, the reaction was classified as IR; when this 171 
interval was longer, it was considered an NIR5,32. 172 
Skin testing 173 
For reactions suggestive of an IR, skin prick tests (SPTs) were carried out as described33 174 
using ciprofloxacin (at 0.02 and 0.2 mg/ml), levofloxacin (at 0.05 and 0.5 mg/ml), and 175 
moxifloxacin (one tablet of 400 mg suspended in NaCI). Intradermal tests were not 176 
performed to avoid false positive results as non-specific histamine release by quinolones 177 
has been reported34,35. 178 
For reactions suggestive of a NIR, patch tests (PTs) were carried out and evaluated as 179 
described33 by mixing powdered quinolone (ciprofloxacin, levofloxacin, and 180 
moxifloxacin) in petrolatum at 30% w/w.  181 
Basophil activation test 182 
In patients with a suspected IR, BATs were performed as described previously27, using 183 
ciprofloxacin (2 and 0.2 mg/ml), levofloxacin (4 and 2 mg/ml), moxifloxacin (2, 0.2 and 184 
0.1 mg/ml), norfloxacin (2, 0.2 and 0.1 mg/ml), ofloxacin (4, 2, 0.2 and 0.1 mg/ml), and 185 
lomefloxacin (4, 2, 0.2 and 0.1 mg/ml).  186 
Drug provocation test 187 
DPTs with ciprofloxacin, levofloxacin, and moxifloxacin were performed in a single 188 
blind manner if skin tests and BATs were negative36: placebo capsules were given at 189 
different times on the first day; increasing doses of quinolones were administered orally 190 
at intervals of 60 min (5, 20, 100 mg for ciprofloxacin and levofloxacin; 5, 30, 65 mg 191 
for moxifloxacin) on the second day. If these did not produce a reaction, three further 192 
doses of quinolones were given on the third day: 125, 125, 250 mg (accumulative dose 193 
500 mg) for ciprofloxacin and levofloxacin; 100, 100, 200 mg (accumulative dose 400 194 
mg) for moxifloxacin. The three test days were separated by 1 week. If cutaneous and/or 195 
respiratory symptoms or alterations in vital signs appeared, the procedure was stopped 196 
and the symptoms were evaluated and treated. If no symptoms appeared during graded 197 
challenge, the therapeutic dose was achieved. This was then followed by taking the full 198 
dose at home, starting 24 hours after the graded challenge. Before beginning the DPT 199 
procedure, patients were stable and their forced expiratory volume in 1s had to be at 200 
least 80% of the predicted value, with an absolute volume of at least 1.5 L. Medications 201 
were stopped before DPT according to international guidelines36.  202 
Statistical analysis 203 
Data analysis was performed using Chi-square analysis to test differences in nominal 204 
variables between groups, the Fisher test was used when there were no criteria for using 205 
the Chi-square test and the Mann–Whitney test was used for quantitative variables. All 206 
reported p values represented two-tailed tests, with values <0.05 considered statistically 207 
significant. A logistic regression analysis was performed to establish the characteristics 208 
associated with the diagnosis of HSR or tolerance to quinolones and with the diagnosis 209 
of immediate anaphylaxis. The following variables were analysed: gender, age, time 210 
interval between drug intake and the onset of the reaction, symptoms experienced, drugs 211 
involved, time interval between drug reaction and study, and number of episodes. 212 
The study was conducted according to the principles of the Declaration of Helsinki. All 213 
the participants were informed orally about the study and signed the corresponding 214 
informed consent.215 
RESULTS  216 
A total of 612 patients with a clinical history suggestive of an HSR to quinolones were 217 
evaluated. Of these, full diagnosis could not be achieved for 442 patients: 361 patients 218 
that gave a negative ST and negative BAT could not undergo DPT to quinolones due to 219 
age, comorbidities or because it was contraindicated due to the potential severity of the 220 
reaction; 78 did not give consent for the allergological tests (STs, BAT and/or DPTs); 221 
and 3 were excluded due to pregnancy. For the remaining 170 patients a full diagnosis 222 
could be achieved: 128 were confirmed as having HSRs to quinolones and 42 as non-223 
allergic (tolerant) to quinolones.  224 
Clinical data of the subjects included in the study 225 
The 170 included subjects with confirmed diagnosis had a median age of 53 226 
[interquartile range: 40–63.25] years, and 126 (74.1%) were female. The majority of 227 
cases reported only one previous episode induced by quinolone intake, except for 2 228 
cases who reported 2 previous IRs. As such, the patients included in the study reported a 229 
total of 172 previous reactions: 120 IRs and 52 NIRs, with the percentage of IRs higher 230 
in those confirmed as having HSRs compared to the tolerant group (73.8% vs 19%; 231 
p<0.0001) (Table 1). Most reported reactions were induced by oral quinolones (142; 232 
82.5%), the rest by intravenous route (30;17.4%). In terms of the symptoms of reported 233 
reactions, the percentage of anaphylaxis reactions was higher in subjects confirmed as 234 
having HSR (p<0.0001); whereas urticaria (p=0.0004), local reaction at the site of IV 235 
administration (p=0.0001) and MPE (p=0.03) were more frequently report by subjects 236 
that were found to be as tolerant (Table 1). Moxifloxacin was the most frequent culprit 237 
quinolone in patients with confirmed HSRs; ciprofloxacin was more frequent in subjects 238 
confirmed as tolerant (p<0.0001 and p=0.001, respectively) (Table 1). In subjects 239 
confirmed as having HSRs, most cases of anaphylaxis were induced by moxifloxacin 240 
(52.9%; p=0.002); urticaria and angioedema were mostly induced by ciprofloxacin 241 
(48.8% and 66.7%, respectively), although these differences was not found to be 242 
statistically significant (Table E1). For those found to be tolerant, ciprofloxacin was the 243 
most frequent cause of both urticaria and angioedema (69.2% and 66.7%, respectively), 244 
as well as of local reactions at the site of IV administration (66.7%) (p>0.05) (Table 245 
E1).  246 
The logistic regression analysis showed that the risk of being confirmed as HSR was 247 
higher for cases who reported moxifloxacin-induced anaphylaxis (OR: 96.16; CI: 6.172-248 
Inf; p=0.009) and for those reporting IRs (OR: 18.856; CI: 5.196-271.449; p<0.0001) 249 
compared to cases who reported other symptoms induced by other quinolones and 250 
NIRs. Moreover, the risk for being confirmed as HSR decreased when ciprofloxacin 251 
was the culprit (OR: 0.107; CI: 0.002-0.741; p=0.04) and the symptoms reported were 252 
MPE, FDE, urticaria, angioedema (OR: 0.053; CI: 0-0.452; p=0.03), or a local reaction 253 
at the site of IV administration (OR: 0.001; CI: 0-0.016; p=0.0006). No significant 254 
associations were found for the other variables, and there were no interactions between 255 
variables. 256 
Analysis of the patients confirmed as suffering HSRs to quinolones 257 
In patients confirmed as having HSRs, a total of 112 reported reactions (73.8%) were 258 
IRs and 18 (26.2%) NIRs. No differences were found when comparing age, sex, atopy, 259 
allergen sensitization and underlying diseases between IR and NIR groups (data not 260 
shown).   261 
Anaphylaxis was the most frequent reported symptom among IRs (p<0.0001) and 262 
urticaria among NIRs (p>0.05) (Table 2). It is of note that the 7 (25%) of patients 263 
reporting reactions within the interval of 1-6 hours showed symptoms compatible with 264 
anaphylaxis. Moxifloxacin was the most frequent quinolone involved in IRs and 265 
ciprofloxacin in NIRs (41.1% and 38.9%, respectively) (Table 2). Anaphylaxis was 266 
induced primarily by moxifloxacin in IRs (52.9%; OR=2.935 (IC:1.418-6.075), 267 
p=0.003)  whereas most urticaria and angioedema was induced by ciprofloxacin (52.9% 268 
and 75%, respectively). Considering NIRs, moxifloxacin was the culprit in most cases 269 
reporting urticaria (42.8%) and ciprofloxacino in angioedema reporting-cases (50%) 270 
(Table E2). The time interval between intake and onset of the reaction was shorter when 271 
the drug was administered by an IV route compared to the oral route (5 [IR: 5-10] 272 
minutes vs 30 [IR: 15-60] minutes, p=0.005). This comparison was also statistically 273 
significant when ciprofloxacin was the culprit (IV route: 5 [5-10] minutes; oral route: 30 274 
[18.7-165] minutes; p=0.01) (Table E3).  275 
Methods used for diagnosis 276 
The median time interval between the reaction and the study was 150 days [interquartile 277 
range: 60-365] (mean: 560.3 days, SD: 1028.4 days). No differences were found 278 
between IRs and NIRs. STs were performed on 54 subjects, BATs on 76, and DPTs on 279 
48. No differences were found when comparing the clinical characteristics of patients 280 
undergoing the different tests (data not shown).  281 
Skin tests 282 
SPTs were performed on 48 patients and PTs on 6, of which 22 were positive: 20 SPTs  283 
and 2 PTs. Of the positive SPTs, 13 (43.33%) were positive to moxifloxacin, 7 (8.53%) 284 
to ciprofloxacin, and 6 (9.83%) to levofloxacin (Table 3). When ciprofloxacin was the 285 
suspected culprit drug, SPTs to ciprofloxacin were positive in 16.7% of the tests and 286 
levofloxacin in 22.2%; when levofloxacin was the suspected culprit, 25% of SPTs were 287 
positive to levofloxacin and 80% to moxifloxacin. Finally, when the suspected culprit 288 
was moxifloxacin, 100% of SPTs were positive to moxifloxacin and 6.2% to 289 
ciprofloxacin (Table 3). Regarding the symptomatology of the reported reactions, the 290 
highest percentage of positive ST results was found for anaphylaxis (53.8%), followed 291 
by urticaria (33.3%). Although the interval between the last quinolone-induced reaction 292 
and the study was shorter in patients with positive STs compared to negative, no 293 
statistical difference was found (90 [interquartile range: 60-240] vs 120 [interquartile 294 
range: 60-172.5] days; p=1). 295 
Basophil activation test 296 
The BAT was positive in 68 (89.5%) of cases. A total of 56 (76.7%) cases were positive 297 
to ciprofloxacin, 35 (53.8%) to moxifloxacin, 26 (44.1%) to levofloxacin, 15 (83.3%) to 298 
norfloxacin, 10 (58.8%) to ofloxacin and 10 (55.5%) to lomefloxacin (Table 4). When 299 
ciprofloxacin was the culprit, BAT to ciprofloxacin was positive in 80%, to 300 
moxifloxacin in 60% and to levofloxacin in 47.4%; when levofloxacin was the culprit, 301 
BAT was positive to ciprofloxacin in 72.7%, to levofloxacin in 45.4% and to 302 
moxifloxacin in 20%; finally, when the culprit drug was moxifloxacin, BAT was 303 
positive to ciprofloxacin in 76.5%, to moxifloxacin in 62.5% and to levofloxacin in 304 
46.2% (Table 4). BAT was positive in 48 out of 49 (97.9%) cases reporting 305 
anaphylaxis, in 13 out of 18 (72.2%) cases of urticaria and in 5 (100%) cases of 306 
angioedema. Although the interval between the historical quinolone reaction and 307 
whether the patients were found to be allergic or not in the study was shorter in patients 308 
who gave a positive BAT compared to negative,  no statistical differences were found 309 
(150 [interquartile range: 60-365] vs 395 [interquartile range: 60-1003.7] days; 310 
p=0.9909). 311 
Drug provocation test 312 
We performed 58 DPTs in 48 patients. A total of 34 DPTs with the culprit quinolone 313 
were carried out in cases with negative ST and BAT, all of which were positive: 23 in 314 
IR (16 with ciprofloxacin, 3 with levofloxacin, and 4 with moxifloxacin) and 11 in NIR 315 
(5 with ciprofloxacin, 2 with levofloxacin, and 4 with moxifloxacin). When the benefit 316 
was considered to outweigh the risk, we carried out DPTs with an alternative quinolone 317 
in 24 cases, this was positive for 13 of these (11 IR and 2 NIR) (Table 5). When 318 
ciprofloxacin was the culprit, DPT to levofloxacin was positive in 60%; when 319 
levofloxacin was the culprit, DPT was positive to ciprofloxacin in 40%; when the 320 
culprit drug was moxifloxacin, DPT was positive to ciprofloxacin in 62.5%, and no case 321 
reacted to levofloxacin (Table 5). In all cases DPTs with quinolones induced mild 322 
symptoms (pruritus and wheals localized on different parts of the body) that 323 
disappeared 1-48 hours after administering antihistamine and corticosteroid treatment.  324 
DISCUSSION 325 
Although hypersensitivity reactions (HSRs) to quinolones represent an important health 326 
problem21, no large-scale study of patients suffering from them exists. To our 327 
knowledge, this is the largest published series of HSRs to quinolones to date. In our 328 
study, more than the 50% of patients reported anaphylaxis, most of whom suffered from 329 
immediate reactions (IRs), in agreement with previously published short 330 
series24,26,27,30,34. Moreover, data suggests that the risk of an HSR is different depending 331 
on the quinolone. Analyses of spontaneous reports implicate moxifloxacin triggers 332 
anaphylaxis in a higher proportion of cases than levofloxacin or ciprofloxacin8,9,37, 333 
which is in line with our results. Indeed, the risk of experiencing anaphylaxis was 2.2-334 
fold higher when moxifloxacin was the culprit, which agrees with previously published 335 
data8,9,37. This may be due to the expanded use of quinolones or increased 336 
immunogenicity to newer quinolones. 337 
The interval between drug intake and the appearance of symptoms is crucial for 338 
evaluating allergic reactions to drugs. Historically, reactions occurring less than one 339 
hour after drug intake are considered IRs, and those occurring after an hour are 340 
considered NIRs5,38. The former are thought to be induced by an IgE-mediated response, 341 
although an alternative non-IgE dependent mechanism may also be involved10,11. For the 342 
latter, the underlying mechanism remains a matter of debate, especially for those with a 343 
time interval of 1 to 6 hours after drug intake39-41. For betalactam antibiotics, the 344 
mechanism has been proposed to be non-IgE dependent, as some evidence suggests that 345 
these reactions are T-cell mediated40-41. On the other hand, for metamizole, a study of 346 
reactions occurring 1–8 hours after intake using basophil activation testing support an 347 
IgE-mediated42. However, to our knowledge, this mechanism has not yet been studied 348 
for quinolones. In this study, we have observed that around 25% of patients reported 349 
anaphylaxis 1 hour after quinolone intake, and more than 40% of them showed positive 350 
results via BAT or SPT, suggesting that an IgE mechanism is likely. The interval 351 
between drug administration and reaction onset may be related to the production of as-352 
yet unidentified metabolites and the route of administration. However, most patients in 353 
our study took the quinolone orally and no differences could be found in terms of 354 
administration route when considering drugs involved and symptoms reported. As such, 355 
we would suggest that the classification of reactions as IR or NIR based solely on a 1 356 
hour cut-off does not sufficiently reflect the extension of the pathophysiology of the 357 
reactions.  358 
The diagnosis of HSRs to quinolones is still a matter of debate. A detailed clinical 359 
history is crucial as a first approach. We found that the chance of being confirmed as 360 
having an HSR to quinolones was 96 times higher in patients who reported 361 
moxifloxacin-induced anaphylaxis and 18 times higher in those reporting IRs. This risk 362 
decreased when ciprofloxacin was the culprit and the symptoms experienced in the 363 
reported reaction were MPE, FDE, urticaria, angioedema or a local reaction at the site 364 
of the administration of the drug. Concerning STs, there is controversy regarding their 365 
utility. Some authors consider they are useful, with a sensitivity of 71%, specificity of 366 
86%, and positive and negative predictive values of 50% and 94%, respectively having 367 
been reported previously24. However, other studies suggest that STs are not valid 368 
because they can produce false-negatives34,35, potentially missing important reactions 369 
and putting patients at risk, moreover they can also produce a large number of false-370 
positive results when tested at high concentrations, which is attributed to non-specific 371 
histamine release by quinolones due to mast cell activation35,43-48. We decided not to 372 
perform intradermal tests in our patients based on this consideration. In our study, we 373 
found a low sensitivity for STs in general, although it was higher for severe reactions 374 
(anaphylaxis) and when levofloxacin and ciprofloxacin were the culprits.  375 
We found the BAT to be useful for the diagnosis of patients with IRs to quinolones27-29. 376 
However, other studies have shown contradictory results30,31. Here, BAT gave a higher 377 
percentage of positive results than STs, agreeing with previous studies27,28. This is 378 
important, because if BATs can be used to confirm diagnosis instead of DPTs in some 379 
cases, this will reduce patient risk. This is particularly useful here, given that the most 380 
common clinical entity induced by quinolones is anaphylaxis. 381 
Although cross-reactivity among quinolones remains a controversial issue, DPTs could 382 
be useful to find safe alternative quinolones. A high degree of cross-reactivity has been 383 
reported between the first- and second- generation quinolones22. Regarding the second 384 
generation, cross-reactivity does not always occur within this group43,45,49, which may 385 
be due to the production of different metabolites. The same phenomenon can occur for 386 
the newer (moxifloxacin) and the second- (ciprofloxacin) and third-generation 387 
(levofloxacin) quinolones50-52. A low degree of cross-reactivity has been found between 388 
levofloxacin and ciprofloxacin34. In our study, 60% of the patients who reported 389 
reactions induced by levofloxacin tolerated ciprofloxacin in DPT and 40% of cases 390 
tolerated levofloxacin when the reactions were induced by ciprofloxacin. DPT with 391 
levofloxacin was carried out for 2 cases who reported moxifloxacin-induced reactions, 392 
with neither patient experiencing an adverse reaction. Based on the data obtained from 393 
our large series of cases, we propose an algorithm for the diagnosis of quinolone-394 
induced HSRs, as described in Figure 1. 395 
A limitation of this study is the high percentage of patients for whom we were not able 396 
to confirm the diagnosis due contraindication or patient refusal. This could be the 397 
reason why the number of cases confirmed as tolerant in our series is low. However, 398 
despite this, our results show relevant differences in clinical characteristics comparing 399 
tolerant and cases confirmed as HSRs, highlighting the importance of a detailed clinical 400 
history as an initial approach for diagnosis. Another limitation of our study is that ST, 401 
BAT, and DPT could not be performed for all patients and with all quinolones, that PT 402 
was carried out at a 30% dilution in petrolatum which could increase the rate of false 403 
negative results, and that the time interval between the reaction and the allergy 404 
evaluation was not uniform in all patients. However, our aim was to describe the role 405 
and utility of the different diagnostic methods performed in a large group of patients in 406 
real allergological practice, not finding differences in the clinical characteristics when 407 
comparing groups of patients based on results for ST, BAT, and DPT.  408 
The accurate diagnosis of quinolone-induced HSRs is an important issue not only due to 409 
their frequency, as described above, but also due to the fact that an important percentage 410 
of patients that report quinolone-induced HSRs report previous reactions to betalactams, 411 
drastically reducing their therapeutic options16. Referring patients with quinolone-412 
induced HSRs for a full allergological evaluation is crucial to confirm or dismiss their 413 
reported allergy. 414 
  415 
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Table 1. Clinical data for the reactions reported by the subjects included in the study, comparing cases confirmed as having HSRs to quinolones 570 
and those confirmed as tolerant to these drugs. AE: Angioedema. FDE: Fixed drug eruption. HSR: Hypersensitivity reaction. MPE: 571 









symptoms; n (%) 
Anaphylaxis 70 (53.8) - <0.0001 
Urticaria 41 (31.5) 26 (61.9) 0.0004 
AE 12 (9.2) 6 (14.3) 0.3522 
FDE 4 (3.1) - 0.5732 
MPE 3 (2.3) 4 (9.5) 0.03 
Local reaction at the site of intravenous 
administration 
- 6 (14.3) 0.0001 
Drugs involved in 
historical reactions; n 
(%) 
Ciprofloxacin 49 (37.7) 28 (66.7) 0.001 
Levofloxacin  21 (16.2) 10 (23.8) 0.2618 
Moxifloxacin  52 (40) 2 (4.8) <0.0001 
Norfloxacin 3 (2.3) 2 (4.8) 0.5967 
Ofloxacin 1 (0.8) - 1 
Pipemidic acid 2 (1.5) - 1 
Unknown 2 (1.5) - 1 
Time interval intake-reaction, 
median (IR) (min) 
30 (11.25-60) 7200 (2880-8640) <0.0001 
Time interval intake-reaction ≤1h; n (%) 112 (73.8) 8 (19) 
<0.0001 
Time interval intake-reaction >1h; n (%) 18 (26.2) 34 (81) 
Administration route; n (%) 
Oral 109 (83.8) 33 (78.6) 
0.4335 
Intravenous 21 (16.1) 9 (21.4) 
Number of episodes, median (IR) 1 (1-1) 1 (1-1) 0.08 
 575 
Table 2.  Clinical data for the reported reactions in cases confirmed as HSRs to 






Immediate                      
n (%) 
Non-immediate        
n (%) 
p 





Urticaria 34 (30.4) 7 (38.9) 0.4696 
AE 8 (7.1) 4 (22.2) 0.04 
FDE - 4 (22.2) 0.0002 
MPE - 3 (16.7) 0.002 
     
Drugs involved 
in historical 
reaction; n (%) 
Ciprofloxacin 42 (37.5) 7 (38.9) 0.9101 
Levofloxacin 17 (15.2) 4 (22.2) 0.451 
Moxifloxacin 46 (41.1) 6 (33.3) 0.5339 
Norfloxacin 2 (1.8) 1 (5.6) 0.3629 
Ofloxacin 1 (0.9) - 1 
Pipemidic acid 2 (1.8) - 1 
Unknown 2 (1.8) - 1 
 
Table 3. Results of SPTs according to the drugs involved and the drug tested. 
Drugs tested; positive cases/cases in which the test was performed (%) 










Ciprofloxacin 3/18 (16.7%) 2/9 (22.2%) - 5/27 (18.5%) 
Levofloxacin 0/8 2/8 (25%) 4/5 (80%) 6/21 (28.6%) 
Moxifloxacin 1/16 (6.2%) 0/9 7/7 (100%) 8/34 (23.5%) 
Norfloxacin 0/1 0/1 - 0/2 
Pipemidic 
acid 
2/2 (100%) 1/1 (100%) 1/1 (100%) 4/4 (100%) 
Unknown 1/1 (100%) 1/1 (100%) 1/1 (100%) 3/3 (100%) 
Total 7/46 (15.2%) 6/29 (20.7%) 13/14 (92.8%) 
Table 4. Results of BATs according to the drugs involved and the drug tested. 
 
  Drugs tested; positive cases/cases in which the test was performed (%) 










Ciprofloxacin 20/25 (80%) 9/19 (47.4%) 12/20 (60%) 5/6 (83.3%) 2/6 (33.3%) 4/6 (66.7%) 24/26 (92.3%) 
Levofloxacin 8/11 (72.7%) 5/11 (45.45%) 2/10 (20%) 1/1 (100%) - 0/1 10/12 (83.3%) 
Moxifloxacin 26/34 (76.5%) 12/26 (46.2%) 20/32 (62.5%) 9/10 (90%) 8/10 (80%) 6/10 (60%) 32/35 (91.4%) 
Norfloxacin 1/1 (100%) 0/1 0/1 - - - 1/1 (100%) 
Ofloxacin 1/1 (100%) 0/1 1/1 - - - 1/1 (100%) 
Unknown 0/1 0/1 0/1 0/1 0/1 0/1 0/1 
Total 56/73 (76.7%) 26/59 (44.1%) 35/65 (53.8%) 15/18 (83.3%) 10/17 (58.8%) 10/18 (55.5%)  
Table 5. Results of DPTs performed according to the drugs involved and the drug 
tested. 
Drugs used in DPT; positive cases/cases in which 
the test was performed (%) 






which the test 
was performed 
(%) 
Ciprofloxacin 21/21 3/5 (60%) - 
Levofloxacin 2/5 (40%) 5/5 0/1 
Moxifloxacin 5/8 (62.5%) 0/2 8/8 
Norfloxacin 1/1 (100%) 1/1 (100%) - 
Unknown - 1/1 (100%) - 
FIGURE LEGENDS 
Figure 1. Algorithm proposed for the diagnosis of quinolone induced-HSRs. AGEP: 
Acute generalized exanthematous pustulosis. DPT: Drug provocation test. PT: Patch 
test. SJS: Stevens-Johnson syndrome. SPT: Skin prick test. TEN: Toxic epidermal 
necrolysis.   
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Table E1. Analysis of the drug involved in each reaction according to the symptoms reported for cases confirmed as having HSR to quinolones 
and those confirmed as tolerant. The percentages are given for the symptoms reported (columns). AE: Angioedema. FDE: Fixed drug eruption. 
HSR: Hypersensitivity reaction. IV: Intravenous. MPE: Maculopapular exanthema.
 HSR Tolerant 
 Anaphylaxis  Urticaria AE FDE MPE  Urticaria AE MPE 
Local 









 18 (69.2) 4 (66.7) 2 (50) 4 (66.7) 
 






2 (33.3) 2 (50) 2 (33.3)  
Moxifloxacin 37 (52.9) 11 (26.8) 2 (16.7) 2 (50) -  2 (7.7) - - -  
Norfloxacin - 2 (5.8) - 1 (25) -  2 (7.7) - - -  
Ofloxacin 1 (1.4) - - - -  - - - -  
Pipemidic acid 1 (1.4) 1 (2.4) - - -  - - - -  
Unknown 1 (1.4) 1 (2.4) - - -  - - - -  
p 0.002 0.2366 0.3949 0.2391 
0.420
1 
 0.2759 0.8126 0.5244 0.8126  
Repository - Unmarked E Tables
Table E2. Quinolones involved in the reported reactions according to the symptoms experienced in cases confirmed as HSR to quinolones. . AE: 













 Immediate; n (%) Non-immediate; n (%) 
 Anaphylaxis Urticaria AE  Urticaria AE FDE MPE  
Ciprofloxacin 18 (25.7) 18 (52.9) 6 (75)  2 (28.6) 2 (50) 1 (25) 2 (66.7)  
Levofloxacin 12 (17.1) 4 (11.8) 1 (25)  2 (28.6) 1 (25) - 1 (33.3)  
Moxifloxacin 37 (52.8) 8 (23.5) 1 (25)  3 (42.8) 1 (25) 2 (50) -  
Norfloxacin - 2 (5.9) -  - - 1 (25) -  
Ofloxacin 1 (1.4) - -  - - - -  
Pipemidic 
acid 
1 (1.4) 1 (2.9) -  - - - -  
Unknown 1 (1.4) 1 (2.9) -  - - - -  
p 0.001 0.01 0.3937  0.6894 1 0.2154 0.511  
Table E3. Comparison of time interval between drug intake and the onset of the reaction 
for oral and intravenous routes, according to the quinolone involved and the symptoms 
reported in the reaction. AE: Angioedema. FDE: Fixed drug eruption. MPE: 
Maculopapular exanthema. 
Time interval between drug intake and reaction 
onset mediane (IR) minutes 
Oral Intravenous p 
Drugs 
involved     
Ciprofloxacin 30 (18.7-165) 5 (5-10) 0.01 
Levofloxacin 30 (17.5-240) - - 
Moxifloxacin 30 (10-30) - - 
Norfloxacin 27.50 (26.2-28.75) - - 
Ofloxacin 17.5 (11.2-23.75) - - 
Pipemidic acid 70 (45-95) - - 




reactions   
Anaphylaxis 30 (10-30) 7.5 (5-10) 0.04 
Urticaria 30 (30-120) 5 (5-5) 0.1479 
AE 600 (240-2880) 17.5 (11.2-23.7) 0.118 
FDE 1740 (1170-2310) - - 
MPE 720 (660-1800) - - 
